US 11,789,020 B2
Neutralizing antibody testing and treatment
Sergei Svarovsky, San Diego, CA (US); Douglas Lake, Scottsdale, AZ (US); Alim Seit-Nebi, San Diego, CA (US); and Maria González-Moa, San Diego, CA (US)
Assigned to Sapphire Biotech, Inc., San Diego, CA (US)
Filed by Sapphire Biotech, Inc., San Diego, CA (US); and ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, Scottsdale, AZ (US)
Filed on May 12, 2021, as Appl. No. 17/319,081.
Claims priority of provisional application 63/023,646, filed on May 12, 2020.
Claims priority of provisional application 63/116,749, filed on Nov. 20, 2020.
Prior Publication US 2021/0356465 A1, Nov. 18, 2021
Int. Cl. G01N 33/569 (2006.01); G01N 33/543 (2006.01)
CPC G01N 33/56983 (2013.01) [G01N 33/54346 (2013.01); G01N 33/54388 (2021.08); G01N 2333/165 (2013.01); G01N 2469/20 (2013.01); G01N 2800/26 (2013.01)] 54 Claims
 
1. A method for detection and measurement of neutralizing antibody levels to SARS-COV-2 in a test-specimen, said method comprising:
obtaining a test-specimen from a subject;
transferring the test-specimen to a sample well of a test-cassette, wherein the cassette further comprises a sample pad, a conjugate pad, a nitrocellulose membrane and an absorbent pad, wherein the sample pad and/or conjugate pad comprises ACE2 or a functional fragment thereof prior to introduction of a sample, wherein the conjugate pad comprises a viral-ACE2-binding protein coupled to a label prior to introduction of a sample;
adding a buffer; and
reading the results from the test-cassette.